← All Cytosorbents CORP filings

Cytosorbents CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
CTSO
Cytosorbents CORP
10-K/A: CytoSorbents Corp. Files 2025 Annual Report Amendment
CytoSorbents Corporation has filed an amendment to its 2025 Form 10-K, primarily to include Part III disclosures and updated executive certifications.
NASDAQ
CTSO
Cytosorbents CORP
10-K: CytoSorbents posts narrower loss; FDA path reset
CytoSorbents grew 2025 revenue 4% and improved margins but flagged going concern risks, Nasdaq noncompliance, and a reset FDA path for DrugSorb-ATR after a 2025 De Novo denial.
NASDAQ
CTSO
Cytosorbents CORP
10-K: CytoSorbents Reports 2024 Results, Awaits Key Regulatory Decisions for DrugSorb-ATR
CytoSorbents Corporation files its 2024 10-K, highlighting revenue growth, reduced operating losses, and progress towards regulatory approval for DrugSorb-ATR.
NASDAQ
CTSO
Cytosorbents CORP
10-K: CytoSorbents Corporation 2023 Annual Report: Focus on Growth and Regulatory Approvals
CytoSorbents Corporation's 2023 annual report highlights a year of strategic advancements, including progress in clinical trials and regulatory submissions, alongside ongoing commercialization efforts.